Previous close | 766.00 |
Open | 773.49 |
Bid | 766.60 x 1400 |
Ask | 782.59 x 3800 |
Day's range | 764.00 - 773.49 |
52-week range | 676.60 - 1,134.00 |
Volume | |
Avg. volume | 4,492 |
Market cap | 1.549T |
Beta (5Y monthly) | 0.43 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 41.17 (5.39%) |
Ex-dividend date | 04 Apr 2024 |
1y target est | N/A |
The FDA approves Bristol Myers' (BMY) cancer drug Augtyro for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Bristol Myers Squibb (BMY) reachead $43.02 at the closing of the latest trading day, reflecting a +1.06% change compared to its last close.